CD274 and colonic neoplasm: The example provided in Fig. 3a–c shows the DDPP intensity plots of three patients treated with IO (pembrolizumab (anti-PD-1), atezolizumab (anti-PDL-1), and nivolumab (anti-PD-1)); two patients had colon cancer (CRC) and one HN cancer.